McKesson Co. (NYSE:MCK) Shares Sold by Calamos Advisors LLC

Calamos Advisors LLC decreased its position in McKesson Co. (NYSE:MCK) by 22.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 54,816 shares of the company’s stock after selling 16,012 shares during the quarter. Calamos Advisors LLC’s holdings in McKesson were worth $25,379,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. AIA Group Ltd acquired a new stake in McKesson in the fourth quarter valued at approximately $1,574,000. Wright Investors Service Inc. increased its stake in McKesson by 39.6% in the fourth quarter. Wright Investors Service Inc. now owns 5,902 shares of the company’s stock valued at $2,733,000 after purchasing an additional 1,673 shares during the last quarter. HF Advisory Group LLC increased its stake in McKesson by 21.0% in the fourth quarter. HF Advisory Group LLC now owns 646 shares of the company’s stock valued at $299,000 after purchasing an additional 112 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt increased its stake in McKesson by 1.4% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 8,582 shares of the company’s stock valued at $3,973,000 after purchasing an additional 119 shares during the last quarter. Finally, KLCM Advisors Inc. increased its stake in McKesson by 15.0% in the fourth quarter. KLCM Advisors Inc. now owns 630 shares of the company’s stock valued at $292,000 after purchasing an additional 82 shares during the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on MCK shares. Citigroup increased their price target on shares of McKesson from $530.00 to $575.00 and gave the company a “buy” rating in a research note on Thursday, February 8th. StockNews.com lowered shares of McKesson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 4th. Mizuho raised their target price on shares of McKesson from $450.00 to $505.00 and gave the stock a “neutral” rating in a research report on Friday, February 9th. Morgan Stanley raised their target price on shares of McKesson from $522.00 to $548.00 and gave the stock an “overweight” rating in a research report on Monday. Finally, Barclays assumed coverage on shares of McKesson in a research report on Wednesday, January 3rd. They set an “overweight” rating and a $537.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $533.50.

McKesson Stock Down 0.1 %

Shares of NYSE MCK traded down $0.48 during mid-day trading on Friday, hitting $518.33. 105,215 shares of the company were exchanged, compared to its average volume of 681,270. The stock has a 50 day simple moving average of $524.44 and a 200-day simple moving average of $485.71. McKesson Co. has a 1-year low of $352.34 and a 1-year high of $543.00. The firm has a market cap of $68.11 billion, a price-to-earnings ratio of 23.51, a price-to-earnings-growth ratio of 1.43 and a beta of 0.45.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, February 7th. The company reported $7.74 earnings per share for the quarter, topping the consensus estimate of $7.05 by $0.69. McKesson had a negative return on equity of 262.63% and a net margin of 0.99%. The firm had revenue of $80.90 billion during the quarter, compared to the consensus estimate of $77.93 billion. During the same period last year, the company earned $6.90 earnings per share. The company’s revenue for the quarter was up 14.8% on a year-over-year basis. Analysts anticipate that McKesson Co. will post 27.59 earnings per share for the current fiscal year.

McKesson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 1st. Shareholders of record on Friday, March 1st were issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 0.48%. The ex-dividend date of this dividend was Thursday, February 29th. McKesson’s dividend payout ratio (DPR) is currently 11.24%.

Insider Buying and Selling at McKesson

In other McKesson news, CEO Brian S. Tyler sold 3,473 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $524.55, for a total value of $1,821,762.15. Following the completion of the sale, the chief executive officer now owns 43,445 shares of the company’s stock, valued at $22,789,074.75. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, CEO Brian S. Tyler sold 3,473 shares of McKesson stock in a transaction on Friday, March 15th. The stock was sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the completion of the transaction, the chief executive officer now owns 43,445 shares of the company’s stock, valued at approximately $22,789,074.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Leann B. Smith sold 186 shares of McKesson stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total value of $92,256.00. Following the transaction, the executive vice president now directly owns 1,511 shares of the company’s stock, valued at approximately $749,456. The disclosure for this sale can be found here. 0.21% of the stock is owned by corporate insiders.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.